Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A.
Vitale C, et al. Among authors: falchi l.
Clin Cancer Res. 2016 May 15;22(10):2359-67. doi: 10.1158/1078-0432.CCR-15-2476. Epub 2016 Jan 5.
Clin Cancer Res. 2016.
PMID: 26733610
Free PMC article.
Clinical Trial.